מדד נזילות מהירה: Plus Therapeutics (PSTV)

Plus Therapeutics, Inc. (PSTV) is striving for dominance in the precision isotope segment for the treatment of metastases and brain tumors. The company is implementing advanced radiopharmaceuticals based on Rhenium-186, investing in scientific research and development. The humanitarian status of the industry ensures stable operations within the US legal framework. The current value of the specific coefficient is 2.10, and the current stock quotes displayed on the GURU.Markets charts allow for an assessment of the asset's dynamics.

The quick ratio measures a company's ability to settle short-term debts using its most liquid assets, completely excluding slow-moving inventories from the calculation. By analyzing operational liquidity trends, an investor can discern the real margin of safety for Plus Therapeutics, Inc. (PSTV), which is critical in the absence of revenue and amid high costs for the clinical development of radiopharmaceuticals.